

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Thomas J. Guttuso, Jr.)	Examiner:
)	To Be Assigned
Serial No.	:	Continuation of 09/879,390)	
)	Art Unit:
Cnfrm. No.	:	To Be Assigned)	To Be Assigned
)	
Filed	:	Herewith)	
)	
For	:	METHOD OF TREATING SYMPTOMS OF)	
		HORMONAL VARIATION, INCLUDING HOT)	
		FLASHES, USING TACHYKININ RECEPTOR)	
		ANTAGONIST)	
)	

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.97-1.98

Mail Stop: Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Dear Sir:

Pursuant to 37 CFR §§ 1.97-1.98, applicant hereby brings to the attention of the United States Patent and Trademark Office, the enclosed references listed on the attached PTO-1449 form.

Pursuant to 37 CFR § 1.98(d), the references identified on the attached PTO-1449 form are not provided, because these references either were previously cited by or submitted to the PTO in parent U.S. Patent Application Serial No. 09/879,390, filed June 12, 2001, of which this application claims priority under 35 USC § 120.

Respectfully submitted,

Date: June 27, 2003


Edwin V. Merkel
Registration No. 40,087

NIXON PEABODY LLP
Clinton Square, P.O. Box 31051
Rochester, New York 14603-1051
Telephone: (585) 263-1128
Facsimile: (585) 263-1600

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO. 176/60807 (6-11405-955)	SERIAL NO. CON of 09/879,390
	APPLICANT Thomas J. Guttuso, Jr.	
	FILING DATE Herewith	GROUP ART UNIT

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE
	1	5,744,156		De Lacharriere et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE
	2	WO 99/09987	03/04/99	WIPO			
	3	WO 98/43639	10/08/98	WIPO			
	4	WO 96/24353	08/15/96	WIPO			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

		5	Hay, "Chronic Obstructive Pulmonary Disease: Emerging Therapies," <u>Current Opinion in Chemical Biology</u> 4:412-419 (2000)
		6	Abraham et al., "Cancer Chemotherapy and Radiation Induced Emesis (CRIE): Current and Future Therapeutic Approaches," <u>Indian Journal of Pharmacology</u> 32:256-268 (2000)
		7	Von Sprecher et al., "Neurokinin Antagonists as Potential Therapies for Inflammation and Rheumatoid Arthritis," <u>Idrugs</u> 1(1):73-91 (1998)
		8	Rance et al., "Hypertrophy and Increased Gene Expression of Neurons Containing Neurokinin-B and Substance-P Messenger Ribonucleic Acids in the Hypothalami of Postmenopausal Women," <u>Endocrinology</u> 128(5):2239-2247 (1991)
		9	Casper et al., "Menopausal Flushes: A Neuroendocrine Link with Pulsatile Luteinizing Hormone Secretion," <u>Science</u> 205:823-825 (1979)
		10	Norheim et al., "Tachykinins in Carcinoid Tumors: Their Use as a Tumor Marker and Possible Role in the Carcinoid Flush," <u>Journal of Clinical Endocrinology and Metabolism</u> 63(3):605-612 (1986)
		11	Conlon et al., "Circulating Tachykinins (Substance P, Neurokinin A, Neuropeptide K) and the Carcinoid Flush," <u>Scand. J. Gastroenterol.</u> 22: 97-105 (1986)
		12	Öberg et al., "The Effects of Octreotide on Basal and Stimulated Hormone Levels in Patients with Carcinoid Syndrome," <u>Journal of Clinical Endocrinology and Metabolism</u> 68(4):796-800 (1989)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO. 176/60807 (6-11405-955)	SERIAL NO. CON of 09/879,390
	APPLICANT Thomas J. Guttuso, Jr.	
	FILING DATE Herewith	GROUP ART UNIT

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRAN- SLATION IF APPRO- PRIATE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

		13	Balks et al., "Effect of a Long-Acting Somatostatin Analogue (Octreotide) on Circulating Tachykinins and the Pentagastrin-Induced Carcinoid Flush," <u>Eur. J. Clin. Pharmacol.</u> 36:133-137 (1989)
		14	Schaffalitzky de Muckadell et al., "Flushing and Plasma Substance P Concentration During Infusion of Synthetic Substance P in Normal Man," <u>Scand. J. Gastroenterol.</u> 21: 498-502 (1985)
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO. 176/60807 (6-11405-955)	SERIAL NO. CON of 09/879,390
	APPLICANT Thomas J. Guttuso, Jr.	
	FILING DATE Herewith	GROUP ART UNIT

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE
	1	5,744,156		De Lacharriere et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE
	2	WO 99/09987	03/04/99	WIPO			
	3	WO 98/43639	10/08/98	WIPO			
	4	WO 96/24353	08/15/96	WIPO			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

		5	Hay, "Chronic Obstructive Pulmonary Disease: Emerging Therapies," <u>Current Opinion in Chemical Biology</u> 4:412-419 (2000)
		6	Abraham et al., "Cancer Chemotherapy and Radiation Induced Emesis (CRIE): Current and Future Therapeutic Approaches," <u>Indian Journal of Pharmacology</u> 32:256-268 (2000)
		7	Von Sprecher et al., "Neurokinin Antagonists as Potential Therapies for Inflammation and Rheumatoid Arthritis," <u>Idrugs</u> 1(1):73-91 (1998)
		8	Rance et al., "Hypertrophy and Increased Gene Expression of Neurons Containing Neurokinin-B and Substance-P Messenger Ribonucleic Acids in the Hypothalami of Postmenopausal Women," <u>Endocrinology</u> 128(5):2239-2247 (1991)
		9	Casper et al., "Menopausal Flushes: A Neuroendocrine Link with Pulsatile Luteinizing Hormone Secretion," <u>Science</u> 205:823-825 (1979)
		10	Norheim et al., "Tachykinins in Carcinoid Tumors: Their Use as a Tumor Marker and Possible Role in the Carcinoid Flush," <u>Journal of Clinical Endocrinology and Metabolism</u> 63(3):605-612 (1986)
		11	Conlon et al., "Circulating Tachykinins (Substance P, Neurokinin A, Neuropeptide K) and the Carcinoid Flush," <u>Scand. J. Gastroenterol.</u> 22: 97-105 (1986)
		12	Öberg et al., "The Effects of Octreotide on Basal and Stimulated Hormone Levels in Patients with Carcinoid Syndrome," <u>Journal of Clinical Endocrinology and Metabolism</u> 68(4):796-800 (1989)
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO. 176/60807 (6-11405-955)	SERIAL NO. CON of 09/879,390
	APPLICANT Thomas J. Guttuso, Jr.	
	FILING DATE Herewith	GROUP ART UNIT

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

		13	Balks et al., "Effect of a Long-Acting Somatostatin Analogue (Octreotide) on Circulating Tachykinins and the Pentagastrin-Induced Carcinoid Flush," <u>Eur. J. Clin. Pharmacol.</u> 36:133-137 (1989)
		14	Schaffalitzky de Muckadell et al., "Flushing and Plasma Substance P Concentration During Infusion of Synthetic Substance P in Normal Man," <u>Scand. J. Gastroenterol.</u> 21: 498-502 (1985)
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

EXPRESS MAIL CERTIFICATE

DOCKET NO.: **176/60807 (6-11406-955)**
APPLICANT: **Thomas J. Guttuso, Jr.**
TITLE: **METHOD OF TREATING SYMPTOMS OF HORMONAL
VARIATION, INCLUDING HOT FLASHES, USING
TACHYKININ RECEPTOR ANTAGONIST**


Certificate is attached to the **Information Disclosure Statement (1 page) and
PTO-1449 (2 page) (in duplicate) with 14 references (not attached)** of the
above-named application.

EXPRESS MAIL NUMBER: **EV138586781US**

DATE OF DEPOSIT: **June 27, 2003**

I hereby certify that this paper or fee is being deposited with the United States
Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on
the date indicated above and is addressed to Mail Stop Patent Application, Commissioner
for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Shawn A. Lockett
(Typed or printed name of person mailing
paper or fee)


(Signature of person mailing paper or fee)